Dyslipidemia
Learn about the latest trends, discover events and innovations in the changing world of dyslipidemia disease.
Science in Dyslipidemia Disease
Get a 360º view and stay up-to-date on cardiovascular disease with content selected for you
Cardiovascular diseases (CVDs) are the leading cause of death globally1
According to the World Health Organization, an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths1. Of these deaths, 85% were due to myocardial infarction or stroke1.
A CV event is a highly traumatic experience for patients and their families2. It takes a heavy emotional toll, brings widespread disability and significantly impedes quality of life3,4.
Prospective evaluation of lipid management following ACS in Saudi Arabia (ACOSYM Study)
Watch the video tackling the critical topic of dyslipidemia management post-acute coronary syndrome. Globally, despite its pivotal role in secondary prevention, the approach remains suboptimal, so we'll dissect Arafah MR et al recent publication, providing a detailed evaluation of lipid management after ACS in Saudi Arabia. Specifically, shining a spotlight on LDL-cholesterol management and delve into the complications of statin use in post-ACS Saudi patients.
Hypercholesterolemia Treatment Patterns and Lipid Target in ACS Patients: HYDRA-ACS Registry
Acute LDL-C Reduction Post ACS: Strike Early and Strike Strong: From Evidence to Clinical Practice
Management of Patients With Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: 1-year Outcomes of The PERI-DYS Study
Prospective evaluation of lipid management following acute coronary syndrome in Saudi Arabia
Inspiration and innovation
Get inspired and stay at the forefront of innovation with the following resources
.webp/jcr:content/jcr_content%20(9).webp)
.webp/jcr:content/jcr_content%20(7).webp)
.webp/jcr:content/jcr_content%20(5).webp)
.webp/jcr:content/Use-of-Lipid-Lowering-Therapies-Over-2-Years-thumb%20(1).webp)
Use of Lipid-Lowering Therapies Over 2 Years
Prescription patterns of lipidlowering therapies over time in patients with atherosclerotic cardiovascular disease
Findings from Gould study
.webp3/jcr:content/jcr_content%20(1).webp)
The European experience: Swedeheart and AIFA registries
Highlights on the most recent real-world data on the use of PCSK9 inhibitors, including those from the Swedeheart and AIFA registries.
.webp/jcr:content/jcr_content%20(16).webp)
.webp/jcr:content/jcr_content%20(21).webp)
Clinical practice experience in patients with familial hypercholesterolemia (FH) from the Safeheart registry
Events
Stay up to date and register for the latest events and view webinar recordings.
.jpg/jcr:content/image%20(28).jpg)